ORMP · Oramed Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.00M | - | $1.34M | $2.70M | $2.70M | $2.71M |
| Cost of Revenue | $1.99M | - | - | - | - | - |
| Gross Profit | $13.0K | - | - | - | - | - |
| R&D | $6.38M | $6.32M | $8.97M | $27.64M | $20.99M | $10.23M |
| SG&A | $8.72M | $6.46M | $8.43M | - | $5.94M | $4.23M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $121.0K | $193.0K | $196.0K | $58.0K | $77.0K | $7.0K |
| Operating Income | ($15.09M) | ($12.78M) | ($15.77M) | ($40.60M) | ($24.22M) | ($11.76M) |
| Interest Expense | - | $2.59M | $2.04M | - | - | - |
| Income Tax | $11.31M | $3.18M | - | $100.0K | - | - |
| Net Income | $64.05M | ($19.10M) | ($36.56M) | ($36.56M) | ($22.99M) | ($11.51M) |
| EPS - Basic | $1.53 | ($0.48) | $0.14 | $0.94 | - | - |
| EPS - Diluted | $1.50 | ($0.48) | $0.14 | $0.94 | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $45.95M | $54.42M | $40.46M | $40.46M | $77.25M | $19.30M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $443.0K | $789.0K | - | - | - | - |
| Current Assets | $133.27M | $143.22M | $162.58M | $157.11M | $95.34M | $40.51M |
| Total Assets | $230.86M | $155.28M | $220.55M | $161.64M | $128.00M | $44.63M |
| Current Liabilities | $19.09M | $5.68M | $53.21M | $5.75M | $6.68M | $4.54M |
| Long-term Debt | - | - | - | $25.0K | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $199.74M | $146.26M | $163.82M | $151.81M | $115.77M | $32.88M |
| Retained Earnings | ($123.44M) | ($176.62M) | ($157.56M) | ($163.08M) | ($114.85M) | ($92.61M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.14M) | ($8.41M) | ($10.29M) | ($27.92M) | ($21.18M) | ($12.44M) |
| Investing Cash Flow | $5.44M | $105.82M | ($73.04M) | $30.21M | ($23.76M) | $4.63M |
| Financing Cash Flow | ($4.74M) | ($52.04M) | $51.98M | $10.78M | $102.89M | $23.79M |
| CapEx | $9.0K | $18.0K | $254.0K | $496.0K | $375.0K | $82.0K |
| Free Cash Flow | ($9.15M) | ($8.43M) | ($10.55M) | ($28.41M) | ($21.56M) | ($12.52M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 0.7% | - | - | - | - | - |
| Operating margin | -754.4% | - | -1176.8% | -1502.0% | -896.2% | -433.8% |
| EBITDA margin | -748.4% | - | -1162.2% | -1499.8% | -893.3% | -433.6% |
| Net margin | 3202.5% | - | -2728.4% | -1352.6% | -850.5% | -424.8% |
| Free cash flow margin | -457.7% | - | -787.2% | -1051.2% | -797.5% | -462.1% |
| FCF / Net income | -0.14 | 0.44 | 0.29 | 0.78 | 0.94 | 1.09 |
| R&D / Revenue | 319.1% | - | 669.5% | 1022.5% | 776.5% | 377.7% |
| SG&A / Revenue | 436.0% | - | 628.7% | - | 219.6% | 156.2% |
| Effective tax rate | 15.0% | - | - | - | - | - |
| Return on assets | 27.7% | -12.3% | -16.6% | -22.6% | -18.0% | -25.8% |
| Return on equity | 32.1% | -13.1% | -22.3% | -24.1% | -19.9% | -35.0% |
| Return on invested capital | - | - | - | -21.1% | - | - |
| Liquidity | ||||||
| Current ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 |
| Quick ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 |
| Cash ratio | 2.41 | 9.57 | 0.76 | 7.04 | 11.57 | 4.25 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.00 | - | - |
| Debt / Assets | - | - | - | 0.00 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -4.9x | -7.7x | - | - | - |
| Equity multiplier | 1.16 | 1.06 | 1.35 | 1.06 | 1.11 | 1.36 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.01 | - | 0.01 | 0.02 | 0.02 | 0.06 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 81d | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 1.9x | - | 16.5x | 12.8x | - | - |
| P / B | 0.6x | 0.7x | 0.6x | 3.1x | - | - |
| P / S | 60.4x | - | 69.9x | 173.6x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | -50.4% | 0.0% | -0.3% | 0.3% |
| Revenue CAGR (3y) | -9.6% | - | -20.9% | 0.0% | 3.3% | 3.3% |
| Revenue CAGR (5y) | -5.9% | - | -11.4% | 1.9% | 33.4% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -18.1% | 18.9% | 61.2% | -67.6% | -106.0% | 19.6% |
| Net income growth (YoY) | - | 47.8% | 0.0% | -59.0% | -99.7% | 19.8% |
| EPS growth (YoY) | - | - | -85.1% | - | - | - |
| EPS CAGR (3y) | 16.9% | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -8.6% | 20.1% | 62.9% | -31.8% | -72.1% | 3.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 36.6% | -10.7% | 7.9% | 31.1% | 252.1% | 69.5% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✓Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ORAMED PHARMACEUTICALS INC. against the 5 most active filers in the same SIC group.
Dividends
$0.25/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Jan 16, 2026 | $0.2500 |